BFLY vs GSK
Butterfly Network, Inc. vs GSK plc — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
GSK
GSK plc
64
Insufficient Data
| Metric | BFLY | GSK |
|---|
| AI Score |
67
|
64
|
| Price |
$9.36
|
$50.91
|
| P/E Ratio |
-32.38×
|
15.80×
|
| ROE |
-39.3%
|
35.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
73.3%
|
| Debt / Equity |
0.10×
|
1.03×
|
| Dividend Yield |
0.0%
|
3.5%
|
| RSI (14) |
66.4
|
39.2
|
| Beta |
2.084
|
0.3
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus GSK.
BFLY leads by 3 points.
BFLY scores 67/100 (Buy) versus GSK at 64/100 (Insufficient Data).
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical